Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.77 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.69 |
| ▸ | IKBKB | O14920 | 4/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.61 |
| ▸ | CHUK | O15111 | 1/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064743 | 0.92 | IKBKB (0.70) | MAPK8MAPK10MAP4K4IKBKBPIK3CG | |
| SCHEMBL4800404 | 0.88 | MAPK8 (0.83) | MAPK8MAPK10IKBKBPIK3CGJAK2 | |
| SCHEMBL4062045 | 0.88 | CAMK2D (0.78) | MAPK8MAPK10IKBKBPIK3CGPIK3CA | |
| SCHEMBL13049909 | 0.87 | PIK3CA (0.66) | MAPK8MAPK10MAP4K4IKBKBPIK3CG | |
| SCHEMBL8312461 | 0.87 | MAPK8 (0.77) | MAPK8MAPK10IKBKBPIK3CGPIK3CA | |
| SCHEMBL13911421 | 0.87 | MAPK8 (0.77) | MAPK8MAPK10IKBKBPIK3CGJAK2 | |
| SCHEMBL13911478 | 0.87 | MAPK8 (0.77) | MAPK8MAPK10MAP4K4IKBKBPIK3CG | |
| SCHEMBL4903457 | 0.87 | MAPK8 (0.81) | MAPK8MAPK10IKBKBPIK3CGJAK2 | |
| SCHEMBL8246523 | 0.87 | MAPK8 (1.00) | MAPK8MAPK10IKBKBPIK3CGJAK2 | |
| SCHEMBL14020973 | 0.86 | MAPK8 (0.68) | MAPK8MAPK10MAP4K4IKBKBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349840-B1 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1349840-B1 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-03-11 | — | — | EP | disclosed |
| CN-101374941-A | Improved composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORP (US) | 2009-02-25 | — | — | CN | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-06-03 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | MAPK6, MAPKAPK2, DUSP6 | MAPK8 18/4885MAPK10 62/4885MAP4K4 66/4885 |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | MAPK8 224/4885MAPK10 845/4885MAP4K4 358/4885 |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | MAP3K1, MAP3K6, MAPKAPK2 | MAPK8 36/4885MAPK10 34/4885MAP4K4 37/4885 |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | MAPK6, MAP3K6, MAPK1 | MAPK8 8/4885MAPK10 56/4885MAP4K4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.